References
Vidaver RM, Shershneva MB, Hetzel SJ et al (2016) Typical time to treatment of patients with lung cancer in a multisite, US-based study. J Oncol Pract 12:e643–e653
Leiro-Fernández V, Mouronte-Roibás C, García-Rodríguez E et al (2019) Predicting delays in lung cancer diagnosis and staging. Thoracic cancer 10:296–303
She Y, He B, Wang F et al (2022) Deep learning for predicting major pathological response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer: a multicentre study. EBioMedicine 86:104364
Forde PM, Spicer J, Lu S et al (2022) Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med 386:1973–1985
Niemeijer A, Leung D, Huisman M et al (2018) Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer. Nat Commun 9:4664
Alberts I, Hünermund J-N, Prenosil G et al (2021) Clinical performance of long axial field of view PET/CT: a head-to-head intra-individual comparison of the Biograph Vision Quadra with the Biograph Vision PET/CT. Eur J Nucl Med Mol Imaging 48:2395–2404
Altorki N, Wang X, Kozono D et al (2023) Lobar or sublobar resection for peripheral stage IA non–small-cell lung cancer. N Engl J Med 388:489–498
Arjomandi Rad A, Vardanyan R, Thavarajasingam SG et al (2022) Extended, virtual and augmented reality in thoracic surgery: a systematic review. Interact Cardiovasc Thorac Surg 34:201–211
Funding
The authors state that this work has not received any funding.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Guarantor
The scientific guarantor of this publication is Dr. Lucian Beer.
Conflict of interest
Lucian Beer: speaker fee from MSD; consulting/advisory board fee from Takeda and Lilly.
Mir Ali Hoda and Martin Heilmann: none.
Maximilian Hochmair: lectures and adboard—MSD, Roche, Lilly, Astra Zeneca, Takeda, Amgen.
Statistics and biometry
No complex statistical methods were necessary for this paper.
Informed consent
Written informed consent was not required.
Ethical approval
Institutional Review Board approval was not required.
Study subjects or cohorts overlap
N/A
Methodology
• commentary
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This article is a part of the ESR Bridges series. The Guest Editor for the ESR Bridges is Regina Beets-Tan (Amsterdam/NL).
Rights and permissions
About this article
Cite this article
Beer, L., Hochmair, M., Heilmann, M. et al. ESR Bridges: imaging and treatment of lung cancer—a multidisciplinary view. Eur Radiol (2024). https://doi.org/10.1007/s00330-023-10523-4
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1007/s00330-023-10523-4